Patents by Inventor Stefano Forte
Stefano Forte has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 12044156Abstract: A method for heating an exhaust pipe in a motor vehicle, comprising including a plurality of spark cycles performed in succession at a preset frequency, wherein each spark cycle includes injecting a-preset fuel quantity into an injection area inside of an exhaust pipe in a motor vehicle and generating at least one spark between the ends of a pair of electrodes located in proximity to the injection area in order to start combustion. Thus, a value of an ionization current flowing between the ends of the pair of electrodes is detected following the extinction of the spark and this ionization current value is compared with a preset reference value. Therefore, the presence of combustion in the spark cycle is determined, if the ionization current value is greater than the preset reference value, or the absence of combustion in the spark cycle, if the ionization current value is lower than the preset reference value.Type: GrantFiled: January 31, 2022Date of Patent: July 23, 2024Assignee: ELDOR CORRPORATION S.P.A.Inventors: Eugenio Carugati, Stefano Silva, Pasquale Forte
-
Patent number: 7666870Abstract: A compound of formula (I): for use in treating cancer or other diseases ameliorated by the inhibition of PARP, wherein: A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X?NRX then n is 1 or 2 and if X?CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are independently selected from the group consisting of hydrogen and C1-4 alkyl, or when X is CRXRY, RC1, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; R1 is selected from H and halo; and Het is selected from: where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N, where only one or two of Y1, Y2 and Y3 can be NType: GrantFiled: June 20, 2008Date of Patent: February 23, 2010Assignee: Maybridge LimitedInventors: Muhammad Hashim Javaid, Graeme Cameron Murray Smith, Niall Morrison Barr Martin, Sylvie Gomez, Vincent Junior Ming-Iai Loh, Xiao-Ling Fan Cockcroft, Stefano Forte, Keith Allan Menear, Ian Timothy William Matthews, Frank Kerrigan
-
Publication number: 20090163477Abstract: A compound of formula (I): for use in treating cancer or other diseases ameliorated by the inhibition of PARP, wherein: A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X?NRX then n is 1 or 2 and if X?CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are independently selected from the group consisting of hydrogen and C1-4 alkyl, or when X is CRXRY, RC1, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; R1 is selected from H and halo; and Het is selected from: where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N, where only one or two of Y1, Y2 and Y3 can be N;Type: ApplicationFiled: June 20, 2008Publication date: June 25, 2009Inventors: Muhammad Hashim Javaid, Graeme Cameron Murray Smith, Niall Morrison Barr Martin, Sylvie Gomez, Vincent Junior Ming-lai Loh, Xiao-Ling Fan Cockcroft, Stefano Forte, Keith Allan Menear, Ian Timothy William Matthews, Frank Kerrigan
-
Patent number: 7407957Abstract: A compound of formula (I): for use in treating cancer or other diseases ameliorated by the inhibition of PARP, wherein: A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are independently selected from the group consisting of hydrogen and C1-4 alkyl, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; R1 is selected from H and halo; and Het is selected from: where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N, where only one or two of Y1, Y2 and Y3 can be N; andType: GrantFiled: August 26, 2005Date of Patent: August 5, 2008Assignees: Maybridge Limited, Kudos Pharmaceuticals LimitedInventors: Muhammad Hashim Javaid, Graeme Cameron Murray Smith, Naill Morrison Barr Martin, Sylvie Gomez, Vincent Junior Ming-lai Loh, Xiao-Ling Fan Cockcroft, Stefano Forte, Keith Allan Menear, Ian Timothy William Matthews, Frank Kerrigan
-
Publication number: 20060063767Abstract: A compound of formula (I): for use in treating cancer or other diseases ameliorated by the inhibition of PARP, wherein: A and B together represent an optionally substituted, fused aromatic ring; X can be NRX or CRXRY; if X=NRX then n is 1 or 2 and if X=CRXRY then n is 1; RX is selected from the group consisting of H, optionally substituted C1-20 alkyl, C5-20 aryl, C3-20 heterocyclyl, amido, thioamido, ester, acyl, and sulfonyl groups; RY is selected from H, hydroxy, amino; or RX and RY may together form a spiro-C3-7 cycloalkyl or heterocyclyl group; RC1 and RC2 are independently selected from the group consisting of hydrogen and C1-4 alkyl, or when X is CRXRY, RC1, RC2, RX and RY, together with the carbon atoms to which they are attached, may form an optionally substituted fused aromatic ring; R1 is selected from H and halo; and Het is selected from: where Y1 is selected from CH and N, Y2 is selected from CH and N, Y3 is selected from CH, CF and N, where only one or two of Y1, Y2 and Y3 can be N; andType: ApplicationFiled: August 26, 2005Publication date: March 23, 2006Applicant: Kudos Pharmaceuticals LtdInventors: Muhammad Javaid, Graeme Smith, Niall Morrison Barr Martin, Sylvie Gomez, Vincent Junior Ming-lai Loh, Xiao-Ling Cockcroft, Stefano Forte, Keith Menear, Ian Timothy William Matthews